Carfilzomib.

Article Details

Citation

Copy to clipboard

Kortuem KM, Stewart AK

Carfilzomib.

Blood. 2013 Feb 7;121(6):893-7. doi: 10.1182/blood-2012-10-459883.

PubMed ID

23393020 [ View in PubMed

]

Abstract

This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib, which was recently approved by the U.S. Food and Drug Administration for treatment of relapsed and refractory multiple myeloma patients who have received at least 2 prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy. This review focuses on clinical trial data leading to drug approval and provides advice for treating physicians who are now accessing this drug for patients.

DrugBank Data that Cites this Article

Drugs

Carfilzomib

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Carfilzomib	Proteasome subunit beta type-5	Protein	Humans	Yes	Inhibitor	Details